Commercial Business Measurement Period Handbook For Patient-Centered Primary Care

Commercial Business Measurement Period Handbook For Patient-Centered Primary Care Measurement Period beginning: 07/01/16 CB Version 070116 V1

Introduction: Welcome to your Commercial Business Measurement Period Handbook. As explained in the Program Description, the Incentive Program gives you the opportunity to share in savings achieved by your Medical Panel during a given Measurement Period. If you meet both quality and cost performance targets, your provider organization could share in the cost savings. To determine whether or how much of a shared savings payment you are eligible for, we measure your performance against quality, utilization and cost targets. In this handbook, you ll have the chance to learn more about those targets and how you can learn more about your performance. Below you will see definitions of some of the most important terms used in this handbook and the details of your Incentive Program: Medical Cost Target Report. Prior to the start of your Measurement Period, or as soon thereafter as practicable, you will be able to access your provider organization s Medical Cost Target (MCT) report via our secure website. The Medical Cost Target report shows medical costs incurred by your Attributed Patients over the course of the Baseline Period. This information is used as the starting point for the projected medical trends used to establish the Medical Cost Targets (MCTs) for the Incentive Program. You are eligible to earn shared savings when the Medical Cost Performance (MCP) during the Measurement Period comes in below the MCT (with consideration to the Risk Corridor), and your measured performance on quality metrics and outcomes meets or exceeds the Program s Quality Gate. Measurement Period Start Date. The first day of the twelve (12) month period during which we measure Medical Cost Performance (MCP) and quality and utilization performance for purposes of calculating shared savings between UniCare and the Medical Panel. Quality Gate. The minimum clinical quality scores that your provider organization must deliver in order to earn any shared savings under the Incentive Program. Your quality gate will be set at 10 th percentile. Further information about the Quality Gate is reviewed in the shared savings section, on page 10. Upside Shared Savings Potential. The maximum percentage of savings under the Incentive Program that you may be entitled to share, as long as your provider organization meets the Quality Gate and other Non-Cost Program Targets. Minimum Risk Corridor (MRC) the percentage of MCT that UniCare retains before sharing any savings with the Medical Panel. This percentage is determined by UniCare and is designed to limit savings payouts that are driven by random variation. Upside Cap The maximum Incentive Program shared savings that you can earn through the Incentive Program. As is the case with the Gross Savings, the Upside Cap is adjusted by the Paid/Allowed Ratio as defined in the Program Description. Performance Scorecard Report. In addition to the MCT report, you will also be able to access your provider organization s Performance Scorecard via our secure website (www.availity.com). The Performance Scorecard shows your performance on the selected clinical, quality and utilization measures listed in this handbook. The Performance Scorecard is a tool to help you assess your quality and utilization performance on a quarterly basis. The information included in this handbook is designed to help you understand your Medical Cost Target report, your Performance Scorecard and the scoring methodology.. 2 CB Version 070116 V1

Table of Contents Introduction:... 2 Section 1: Medical Cost Target... 4 Where to Find Your MCT Report and Supporting Materials... 4 Section 2: Performance Scorecard & Your Measures... 5 Overview... 5 Scorecard Report Example... 5 Quality Measures for Your Measurement Period... 6 Section 3: Calculating Your Shared Savings... 9 Overview... 9 Quality Gate Did you pass the Quality Gate?... 9 Weighting Composites... 12 Calculating Composite Scores... 13 Summary of your scoring... 19 INDEX Scorecard Measure Specifications... 20 3 CB Version 070116 V1

Section 1: Medical Cost Target Overview As part of our Enhanced Personal Health Care Program, we track overall medical costs incurred by our members, and under the incentive portion of the Program, we reward participating providers who are able to provide appropriate care in a cost-effective manner while maintaining or improving performance against nationally recognized quality measures. The Medical Cost Target Report shows medical costs incurred by a given Medical Panel s Attributed Members over the course of the Baseline Period. This information is used to establish the Medical Cost Targets (MCTs) for the Incentive Program. The Medical Cost Target Report lists supporting Member Months, average risk scores and claims expenditures incurred by Attributed Members over the course of the Baseline Period. You are eligible to earn shared savings if your performance during the Measurement Period creates Net Savings (i.e., costs in the Measurement Period come in lower than projected) and if you meet or exceed the Program s quality benchmarks. The better the quality score, the higher the potential shared savings payment. The Medical Cost Target Report is meant to give you a sense of the baseline cost trend from which you are starting. This level-set helps you hit the ground running at the beginning of the Measurement Period for the Incentive Program. This report is produced at the start of each annual Measurement Period. You will receive periodic reports that show your Medical Cost Performance (MCP) over the course of the. Where to Find Your MCT Report and Supporting Materials Your MCT report will be available within 45 days following the start of your Measurement Period or as soon thereafter as practicable. To view your MCT report or to view a useful Quick Reference Guide for MCT, select the Provider Online Reporting link on Availity.com. 4 CB Version 070116 V1

Section 2: Performance Scorecard & Your Measures Overview The performance scorecard is comprised of Clinical Quality and Utilization Measures. In addition to serving as a basis for Incentive Program savings calculations, these measures are used to establish a minimum level of performance expected of you under the Program, and to encourage improvement through sharing of information. The performance scorecard allows you to monitor your progress in these measures throughout the. It will identify: Historic measure rate during the Baseline Period Rolling measure rate Rolling measure numerator and denominator Benchmarks for your Measurement Period Scorecard Report Example The Performance Scorecard report includes information for providers on: Earned Contribution: The proportion of the Shared Savings Potential earned for each Scorecard category and for the overall Program. Maximum Possible Shared Savings: The maximum percentage (out of 100%) of Shared Savings to which the provider is entitled under the Incentive Program. 5 CB Version 070116 V1

Quality Measures for Your Measurement Period Clinical Quality Measures The clinical quality measures for the Program are grouped into two categories: (1) Acute and Chronic Care Management and (2) Preventive Care. These categories are then further broken out into six subcomposites. These measures cover care for both the adult and pediatric populations. Nationally standardized specifications are used to construct the quality measures in conjunction with Plan data. Acute and Chronic Care Management Measures o Medication Adherence - Proportion of Days Covered (PDC): Oral Diabetes - Proportion of Days Covered (PDC): Hypertension (ACE or ARB) - Proportion of Days Covered (PDC): Cholesterol (Statins) o o Diabetes Care - Diabetes: Urine Protein Screening - Diabetes: HbA1c Testing - Diabetes: Eye Exam Annual Monitoring for Persistent Medications - Annual Monitoring for Patients on Persistent Medications: Digoxin - Annual Monitoring for Patients on Persistent Medications: ACE/ARB - Annual Monitoring for Patients on Persistent Medications: Diuretics o Preventive Measures o o Other Acute and Chronic Care Measurement - Appropriate Testing for Children with Pharyngitis - Appropriate Treatment for Children with Upper Respiratory Infection - Osteoporosis Management in Women Who Had a Fracture - Persistence of Beta-Blocker Treatment After a Heart Attack - Arthritis: Disease Modifying Anti-rheumatic Drug (DMARD) Therapy in Rheumatoid Arthritis - Use of appropriate medication for people with Asthma - New Episode of Depression: Effective Acute Phase Treatment - New Episode of Depression: Effective Continuation Phase Treatment Pediatric Prevention - Childhood Immunization Status: MMR - Childhood Immunization Status: VZV - Well-Child Visits Ages 0-15 Months - Well-Child Visits Ages 3-6 Years Old - Well-Child Visits Ages 12-21 Years Old Adult Prevention - Breast Cancer Screening - Cervical Cancer Screening 6 CB Version 070116 V1

Utilization Measures Three different utilization measures are included in the Program scorecard. The measures focus on appropriate emergency room (ER) utilization, management of ambulatory-sensitive care conditions as measured by hospital admissions, and generic dispensing rates for a select set of drug classifications. As with the clinical metrics, administrative data are used to construct the utilization measures. Potentially Avoidable ER Visits This measure was developed using research that determines ER visits that were potentially avoidable by identifying visits that could have been treatable in an ambulatory care setting. Visits for treatment of conditions, such as the following, are considered potentially avoidable: Conjunctivitis Otitis media Sinusitis Bronchitis Sinusitis Gastritis Constipation Urinary tract infection Menstrual disorders Cellulitis Dermatitis Sun burn Osteoarthrosis Joint pain Backache Cramps Insomnia Malaise and fatigue Throat pain Cough Nausea or vomiting alone Diarrhea Sprains Abrasions Contusions First degree burns Strep throat Vaccinations Routine child Prenatal Gynecological and adult exams Change of wound dressings Radiology and laboratory exams Health screenings. Ambulatory Sensitive Care Hospital Admissions The Agency for Healthcare Research and Quality (AHRQ) has developed a Prevention Quality Indicators (PQI) composite measure of 11 potentially avoidable hospitalizations for ambulatory care sensitive conditions that are the basis of this measure. They are: 1. Diabetes short-term complications 2. Diabetes long-term complications 3. Chronic obstructive pulmonary disease or asthma in older adults 4. Hypertension 5. Heart Failure 6. Dehydration 7. Bacterial pneumonia 8. Urinary tract infection 9. Angina without procedure 10. Uncontrolled diabetes 11. Asthma in younger adults 7 CB Version 070116 V1

Generic Dispensing Rate We assess the generic dispensing rate for five classes of medication: 1. Statins 2. ADHD Medications 3. ARBs and ARB Combinations 4. Beta Blockers and Beta Blocker Combinations 5. Serotonin Agonists and Serotonin Agonist Combinations (Migraine Medications) Quality Improvement Measures In addition to assessing performance against thresholds, a subset of the clinical measures (listed below) will be scored for improvement. The selection of these measures is a subset of the current set of performance measures. These improvement measures will be assessed at your provider organization level and will be weighted equally for each measure that has a denominator greater than or equal to 30. If the denominator for each of the improvement measures is less than 30, then we will not use a score for that category. 1. Breast Cancer Screening 2. Medication Adherences: Statins 3. Diabetes: HbA1c Testing 4. Well Child Visits ages 3-6 Years Old 5. Appropriate Testing for Children with Pharyngitis Composite Overview Scorecard points are divided into five categories, or composites. Several of the composites are based upon subcomposites. Then, within some of the sub-composites there are specific care measures. Performance on the clinical measures listed above will be calculated at the sub-composite level. The sub-composites are scored as the sum of the numerators for the measures within the sub-composite divided by the sum of the denominators. Scoring of the clinical measure sub-composites occurs at the provider organization level. If all of the clinical sub-composites have a denominator less than 30, or if the Annual Monitoring for Persistent Medications is the only clinical sub-composite with a denominator of at least 30, then scoring will occur at the Medical Panel-level. The Utilization Measures will always be scored at your Medical Panel-level to achieve sufficient denominator sizes for meaningful measurement. The four major composites are: 1. Acute and Chronic Care Management 2. Preventive Care 3. Utilization 4. Clinical Quality Improvement Composite Details 1. The Acute and Chronic Care Management Composite has four sub-composites. Each of the sub-composites has multiple care measures that contribute to the Acute and Chronic Care Management calculation: Medication Adherence Diabetes Care Annual Monitoring for Persistent Medications Other Acute and Chronic Care Management 8 CB Version 070116 V1

2. The Preventive Care Composite has two sub-composites, with five individual care measures: Adult Preventive Pediatric Preventive 3. The Utilization Composite is made up of three sub-composites: Potentially avoidable ER visits Admissions for ambulatory sensitive care Generic drug dispensing rate for five classifications 4. The Clinical Quality Improvement Composite has four measures, and was outlined previously. Section 3: Calculating Your Shared Savings Overview The opportunity to share in savings that are realized for your Attributed Members is a key characteristic of the Program. After savings are determined, the proportion of shared savings that you can earn depends on your organization s performance on a scorecard. Your Scorecard serves two functions: (1) it will let you know if you met the Quality Gate, and (2) it will show you the overall percentage of the shared savings you earn. Below, we review the four major steps to determine your shared savings: 1. Savings Pool Funded 2. Quality Gate Passed 3. Earned Contribution Calculated for each Composite 4. Overall Shared Savings Potential Calculated Savings Pool Funded Was the savings pool funded? In order to participate in shared savings, the Savings Pool must be funded. For that to happen, your Medical Panel s Attributed Member population must demonstrate savings over the course of your Measurement Period. As described more fully in the Program Description, UniCare will calculate the Savings Pool by comparing the Medical Cost Performance (MCP) for your Attributed Member population for a specified 12 month Measurement Period to the established Medical Cost Target (MCT). In the event that the MCP is less than the MCT, the Savings Pool is funded. After the pool is funded, the Minimum Risk Corridor (MRC) is calculated by multiplying the MCT by the MRC, and then multiplying the result with the Paid/Allowed Ratio (as outlined further in the Program Description). Ultimately, the Savings Pool is multiplied by your Shared Savings Percentage earned to calculate your shared savings payout. Quality Gate Did you pass the Quality Gate? Your provider organization must meet a minimum threshold of performance on clinical quality measures in order for you to share a portion of the savings pool. That threshold, referred to as the Quality Gate, is based on an overall clinical quality score, which is computed by aggregating your scores across the scorecard s clinical sub-composites. We calculate that score for the Measurement Period and compare it to the distribution of performance across the market for the same time period. The market distribution of performance includes provider organizations (including primary care 9 CB Version 070116 V1

and specialist providers, whether participating in the Program or not) that have at least one of the 6 quality subcomposites with a denominator of 30 or more. Your provider organization s clinical quality score must meet or exceed the market 10th percentile to pass the Quality Gate. For provider organizations with denominators of at least 30 in all 6 clinical sub-composites, the sub-composite rates are proportionally weighted by the assigned Shared Savings Potential to arrive at the overall clinical quality score. When provider organizations have one to five sub-composites with denominators of 30 or more, the weights are redistributed accordingly and then a final overall quality composite score is calculated. If your overall quality composite score is greater than the Quality Gate, you are eligible to earn shared savings. Examples follow in the tables below: 10 CB Version 070116 V1

Table 1: Clinical Sub-Composites and Weights for Calculating the Overall Quality Composite: In this example the group had sufficient denominators to be scored in all categories. The Quality Gate, using the 10 th percentile, equates to a 22% performance rate across all sub-composites. When the sub-composite scores are aggregated proportional to the weights, the group has an overall score of 42%. Since the Quality Gate was set at 22%, this group would pass the Quality Gate. Example One Clinical Sub-Composites Performance Rate Weight Medication Adherence 138 62 45% 25.0% 11% Diabetes Care 280 69 25% 12.5% 3% Annual Monitoring for Persist Meds 63 52 83% 5.0% 4% Other Acute and Chronic Care Management 71 51 72% 20.0% 14% Pediatric Preventive 89 18 20% 12.5% 3% Adult Preventive 250 68 27% 25.0% 7% 100% QUALITY GATE 42% Overall Contribution Percentage Table 2: Clinical Sub-Composites and Weights for Calculating the Overall Quality Composite: In this example the group did not have sufficient denominators to be scored in all categories, so the weights were proportionally redistributed accordingly, producing an overall quality composite score of 45%. Since the Quality Gate was set at 22%, this group would pass the Quality Gate. Example Two Clinical Sub-Composites Performance Rate Weight Overall Contribution Percentage Medication Adherence 138 62 45% 28.6% 13% Diabetes Care 280 69 25% 14.3% 4% Annual Monitoring for Persist Meds 63 52 83% 5.7% 5% Other Acute and Chronic Care Management 71 51 72% 22.9% 16% Pediatric Preventive 18 15 NA NA NA Adult Preventive 250 68 27% 28.6% 8% 100% QUALITY GATE 45% 11 CB Version 070116 V1

Weighting Composites The composite, sub-composites, and care measures do not contribute equally to the Scorecard s results they are weighted more heavily toward Clinical Measures: The Acute and Chronic Care composite is weighted more heavily than preventive care. Utilization measures account for 40% of the scorecard points. Table 3: Composite Weights - Example Category Allocation of Shared Savings Potential Clinical: Acute and Chronic Care Management Medication Adherence Diabetes Care Annual Monitoring for Persist Meds Other Acute and Chronic Care Management Pediatric Adult Clinical: Improvement Utilization TOTAL Clinical: Preventive 12 6 2.4 9.6 6 12 12 40 100% Table 4: Shared Savings Potential per Composite in Absolute Terms - Example Category Proportion of Shared Savings Clinical: Acute and Chronic Care Management Medication Adherence 4.20% Diabetes Care 2.10% Annual Monitoring for Persist Meds 0.84% Other Acute and Chronic Care Management 3.36% Clinical: Preventive Pediatric 2.10% Adult 4.20% Clinical: Improvement 4.20% Utilization 14.00% TOTAL 35% 12 CB Version 070116 V1

Calculating Composite Scores As mentioned above, there are five composites that are calculated for the scorecard. Each area is explained in detail below. Composites 1 & 2: Acute and Chronic Care Management and Preventive Care Measures We use four steps to determine the proportion of shared savings earned for the acute and chronic care management and preventive care. The table below is a visual representation of the process. Table 5: The Four Steps That Are Used to Calculate for Preventive Care Measures - Example Organizations Current Performance Market Thresholds Shared Savings Adult Preventive Sub-composite Eligible Population Compliant with Measure Rate Level 1-20th percentile Earned Shared Savings = 30% Level 2-40th Percentile Earned Shared Savings 50% Level 3-60th Percentile Earned Shared Savings 70% Level 4-80th Percentile Earned Shared Savings 100% Measurement Level Earned Contribution Upside Shared Savings Potential Shared Savings Percentage 3303 2049 62% 52% 60% 65% 72% Group 50% 4.20% 2.1% Step 1 Step 2 Step 3 Step 4 Step 1. Calculate sub-composite rate Sub-composite rates are calculated by summing- the numerators (the number compliant with measure) across each of the measures within the sub-composite, and then dividing by the sum of the denominators (eligible population). Step 2. Compare performance to market thresholds Market thresholds are established for each of the sub-composites at the <20th, 20th, 40th, 60th and 80th percentiles for the prior to the Program Measurement Period. Performance thresholds will be provided soon after the start of the Measurement Period The thresholds are set jointly for all lines of business included in the Program using performance of all providers within the market. Provider organizations with a sub-composite denominator less than 30 are excluded from the calculation of the relevant sub-composite thresholds. 13 CB Version 070116 V1

Step 3. Assign percentage of the category earned The four levels of market thresholds are used to categorize four (4) tiers of performance. After passing the lowest market threshold, each performance tier is associated with a greater proportion of earned shared savings: (0 - < 20th percentile) = 0% of shared savings earned Level 1 (20th-<40th percentile) = 30% of shared savings earned Level 2 (40th-<60th percentile) = 50% of shared savings earned Level 3 (60th-<80th percentile) = 70% of shared savings earned Level 4 (80th -<100th percentile) = 100% of shared savings earned Step 4. Calculate shared savings earned After the percentage of the category earned is determined, that value is multiplied by the group s Upside Shared Savings Potential for the Sub-composite. This yields the earned shared savings for the subcomposite. 14 CB Version 070116 V1

Composite 3: Utilization Measures Calculated We use five steps to determine the proportion of shared savings earned for each utilization sub-composite. Table 6 uses sample data to show hypothetical calculations. Table 6: The Five Steps That Are Used to Calculate Utilization Measures - Example Measures Member Months Current Performance Market Benchmark Shared Savings Visits Risk Adj. Factor Risk Adj. Rate Level 1 Level 2 Level 3 Level 4 Upside Shared Savings Potential Earned Contribution Shared Savings % Commercial Adult 98,043 176.00 0.77 27.90 37.71 27.61 21.91 17.65 2.96% 30.00% 0.89% Commercial < 18 18,076 54.00 1.02 35.00 26.12 22.15 17.96 12.27 0.54% 00.00% 0.00% Weighted Subcomposite Total: 3.50% 25.33% 0.89% Step 1 Step 2 Step 3 Step 4 Step 5 Step 1 Calculate utilization rates for the Medical Panel for distinct line of business and age categories. Ambulatory Sensitive Admits and Potentially Avoidable ER measures: o To control for variation in patient mix and associated variable utilization between Medical Panels, utilization rates are calculated separately for: Commercial members at least 18 s of age Commercial members less than 18 s of age o The numerator is the count of qualifying events during the Measurement Period. o The denominator is the sum of Member Months for members attributed to the Medical Panel during the Measurement Period. o The unadjusted rate is computed as (numerator/denominator)*12,000. o This rate is risk-adjusted by dividing the actual raw rate for the provider panel by the relative risk score. o The Medical Panel risk score is calculated as the sum of weighted retrospective Diagnostic Cost Grouping risk scores for members attributed to the Medical Panel, divided by number of Attributed Members with a risk score. That rate is then divided by the average Risk Score of all members within the line of business/age group. Generic Dispensing Rates o To control for variation in patient mix and associated variable utilization between Medical Panels, utilization rates are calculated separately for: Commercial members at least 18 s of age Commercial members less than 18 s of age The Generic Dispensing Rate is calculated separately for each of the five therapeutic classes. = count of all prescriptions for the Medical Panel s attributed patient population within each of the five generic classes. 15 CB Version 070116 V1

o = count of generic prescriptions during Measurement Period within each of the five generic classes. o The rate is computed as (numerator/denominator) percentage for each line of business/age group within each of the five generic classes separately. Step 2 Compare performance to market thresholds. o Market Thresholds are established for each of the utilization measures for three distinct line of business/age groups (commercial adult, commercial <18). o Four levels of thresholds are calculated based on the overall market: <20th, 20th, 40th, 60th and 80th percentiles for the prior to the Program Measurement Period. o We will provide performance thresholds soon after the start of the Measurement Period. Step 3 Determine Shared Savings Potential for each line of business/age group. o Upside shared savings -Potential for the utilization measures: o Potentially avoidable emergency room visits = 3.5% o Generic dispensing rate (GDR) = 7% o Ambulatory sensitive care admissions = 3.5% o Since these measures are assessed by line of business/age groups, the shared savings opportunity for each of these groups must be determined. o Upside shared savings opportunity for each GDR drug class is determined by distributing the overall Upside Shared Savings Potential for GDR (7%) based on the proportion of prescriptions within that drug class compared to the overall (total) GDR prescription count. o Within each drug class, the shared savings opportunity is determined for each line of business age/group based on the proportion of prescriptions within that line of business/age group. Step 4 Assign the earned contribution percentage. The four levels of market thresholds are used to categorize four tiers of performance. After passing the lowest market threshold, each performance tier is associated with a greater proportion of earned shared savings: o (0 - < 20th percentile) = 0% of shared savings earned o Level 1 (20th-<40th percentile) = 30% of shared savings earned o Level 2 (40th-<60th percentile) = 50% of shared savings earned o Level 3 (60th-<80th percentile) = 70% of shared savings earned o Level 4 (80th -<100th percentile) = 100% of shared savings earned Step 5 Calculate earned shared savings for each utilization measure and the overall category. The earned shared savings for each measure/group combination is calculated by multiplying the percentage of the category earned for each line of business/age group for each of the utilization measures by the Medical Panel s Maximum Upside Shared Savings Potential. These scores are summed to determine the overall percentage of shared savings for each of the Utilization Metrics, and then summed for an overall utilization shared savings earned. 16 CB Version 070116 V1

Overall Scoring Summary for Utilization Components The chart below demonstrates how steps 3, 4 and 5, described above, are used to calculate the overall score for the utilization subcomponents. 3. Determine Upside Shared Savings Potential for each line of business/age group. 4. Assign the earned contribution percentage. 5. Calculate earned shared savings for each utilization measure and the overall category. Table 7: Overall scoring for Utilization Measures - Example Step 4 Step 3 Step 5 17 CB Version 070116 V1

Composite 4: Clinical Quality Improvement Components Calculated There are five clinical improvement measures selected from the clinical quality measures as follows: 1. Breast cancer screening 2. Medication adherence: statins 3. Diabetes: HbA1c Testing 4. Well child visits for ages 3-6 Years old 5. Appropriate testing for children with pharyngitis Scoring of this scorecard component is performed only at the individual provider organization level. Performance is measured as follows: Rates are calculated for each of the five clinical improvement measures where the denominator size is 30 or more for both Measurement Periods. Weights for measures with a denominator less than 30 are reallocated to the remaining Improvement Measures. A target rate is set for each of the improvement measures. This target represents an improvement of 20% in closing the quality gap. (1-Group Baseline Rate)*.20)+group baseline rate If the target is achieved, you will receive full credit for that measure. Additionally, if the current rate is 90% or higher, full credit is received. Scoring for Improvement Measures will always take place at the group level. Each of the five improvement measures will be weighted equally at 20%. If your denominator less than 30 for any measure, that measure will not be scored but the weighting will be redistributed to the remaining measures with sufficient denominator size. If none of the five measures have a denominator of 30 or more, no points will be awarded or reallocated for the improvement component. 18 CB Version 070116 V1

Summary of your scoring The tables below pull together all of the scoring that is described in this Measurement Period Handbook. The performance of your Medical Panel is used to calculate a score (0-100%) for each scorecard component. Your shared savings for each scorecard component is calculated by multiplying the Upside Shared Savings Potential (shown above in table 4) by the category score. The sum of your earned shared savings for each scoring components yields your overall earned shared savings examples of this calculation are shown in Tables 8 below. The table below, which you will receive with your scorecard posted to Availity, will show: Whether you passed the Quality Gate, and The overall percentage of shared savings that you have earned for the Measurement Period. Table 8: In this example, the provider organization would earn 20.76 % of a Shared Savings Pool. Summary one - Without NCQA PCMH Recognition - Example Category Passed Quality Gate (10th percentile) ------> (1) Clinical: Acute and Chronic Care Mgmt. 10.50% Savings Potential Category % Earned Medication Adherence 4.20% 70% 2.94% Diabetes Care 2.10% 50% 1.05% Annual Monitoring for Persistent Medications 0.84% 0% 0.00% Other Acute and Chronic Care 3.36% 100% 3.36% (2) Clinical: Preventive 6.30% Pediatric Preventive 2.10% 15% 0.32% Adult Preventive 4.20% 70% 2.94% (3) Clinical: Improvement 4.20% 75% 3.15% (4) Utilization 14.00% 50% 7.00% OVERALL SAVINGS POTENTIAL 35% Savings Earned EARNED SHARED SAVINGS 20.76% YES 19 CB Version 070116 V1

INDEX Scorecard Measure Specifications Acute and Chronic Care Management Measures Sub-composite: Medication Adherence Measure Description / Technical Specifications Measure Citation Proportion of Days Covered (PDC): Oral Diabetes Attributed Members with at least two prescriptions for diabetic oral agents in the who have at least 80% days covered (PDC) since the first prescription of an oral diabetic agent during the. Attributed Members in the denominator with at least 80% days covered for an oral diabetic Rx since the first prescription for the drug during the last 365 days Attributed Members who have at least two prescriptions for an oral diabetic drug during the last 365 days >=80% days covered (PDC) for Diabetic Oral Agents (removing overlapping days for Rx) from index event to end of >=2 Rx claims for diabetic oral agents from end of -365 to end of, saving earliest instance as index event (IE); Rx eligibility from index event to end of using HEDIS gap method, <=1 gap <=45 days max; >=18yo No Rx claims for 'Insulin' from index event to end of CMS Part D Specifications 2014 Proportion of Days Covered (PDC): Hypertension (ACE or ARB) Attributed Members with at least two prescriptions for an ACE/ARB in the who have at least 80% days covered (PDC) since the first prescription of an ACE/ARB during the. Attributed Members in the denominator with at least 80% days covered for an ACE/ARB since the first prescription for the drug during the last 365 days Attributed Members who have at least two prescriptions for an ACE/ARB during the last 365 days Attributed Members in the denominator with at least 80% days covered for a Statin since the first prescription for the drug during the last 365 days Attributed Members who have at least two prescriptions for a Statin during the last 365 days >=80 days covered (PDC) for ACE/ ARB (removing overlapping days) from index event to end of >=2 Rx claims for ACE/ ARB from end of -365 to end of measurement, saving earliest instance as index event (IE); Rx eligibility from index event to end of, using HEDIS gap method, <=1 gap <=45 days max; >=18yo CMS Part D Specifications 2014 Proportion of Days Covered (PDC): Cholesterol (Statins) Attributed Members with at least two prescriptions for a Statin in the who have at least 80% days covered (PDC) since the first prescription of a Statin during the. >=80% days covered (PDC) for Statins (removing overlapping days) from index event to end of >=2 Rx claims for Statins from end of -365 to end of measurement, saving earliest instance as index event (IE); Rx eligibility from index event to end of using HEDIS gap method, <=1 gap <=45 days max; >=18yo CMS Part D Specifications 2014 20 CB Version 070116 V1

Sub-composite: Diabetes Care Measure Description / Technical Specifications Measure Citation Diabetes: Urine Protein Screening Attributed Members between 18 and 75 s old who have diabetes and at least one nephropathy screening; or who had evidence of medical attention for existing nephropathy (diagnosis or treatment of nephropathy), who are taking ACE-I/ARBs, or who have had at least one visit with a nephrologist. The number of Attributed Members from the denominator who during the had at least one test for nephropathy screening; or who had evidence of medical attention for existing nephropathy (diagnosis or treatment of nephropathy), who are taking ACE-I/ARBs, or who have had at least one visit with a nephrologist Attributed Members with diabetes diagnosed during the or the prior to the Any one of the following during the measurement : 1 lab procedure for a urine microalbumin or macroalbumin test 1 procedure or diagnosis for treatment for nephropathy (including dialysis) 1 outpatient visit with a nephrologists specialist 1 Rx claim for ACE Inhibitors/ARBs Age of 18 75 s as of the end of the AND meet NCQA/HEDIS criteria for diabetes diagnosis, identified during the or the prior AND have service eligibility during the AND exclude Attributed Members who meet NCQA/HEDIS criteria for diagnosis of polycystic ovaries any time during the Attributed Member s history through the end of the AND exclude Attributed Members who meet NCQA/HEDIS criteria for diagnosis of gestational diabetes or steroid-induced diabetes in any setting, during the or the prior to the. National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. Diabetes: HbA1c Testing Attributed Members between 18 and 75 s old who have diabetes and who had at least 1 HbA1c test during the measurement. Attributed Members in the denominator who had at least one serum HbA1c test during the measurement Attributed Members with diabetes diagnosed during the or the prior to the 1 claim for a HbA1c test during the measurement Age of 18 75 s as of the end of the ; AND meet NCQA/HEDIS criteria for the diagnosis of Diabetes, identified during the measurement or the prior; AND have service eligibility during the ; AND exclude Attributed Members who meet NCQA/HEDIS criteria for diagnosis of polycystic ovaries any time during the Attributed Member s history through December 31 of the measurement AND exclude Attributed Members who meet NCQA/HEDIS criteria for diagnosis of gestational diabetes or steroid-induced diabetes in any setting, during the or the prior to the. National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 21 CB Version 070116 V1

Measure Description / Technical Specifications Measure Citation Diabetes: Eye Exam Attributed Members between 18 and 75 s old who have diabetes and who had a retinal eye exam from an eye care professional in the last 2 s. Attributed Members in the denominator who received a retinal eye from an eye care professional in the last 730 days. Attributed Members identified as having diabetes during the measurement or the prior to the. 1 claim for a visit with an eye care professional in the last 730 days. Note: HEDIS specifications only count retinal eye exams from the previous if the results were negative, but due to data limitations this measure was loosened to accept all eye exams from the previous regardless of result. Age of 18 75 s as of the end of the AND meet NCQA/HEDIS criteria for diabetes diagnosis, identified during the or the prior AND have service eligibility during the AND exclude Attributed Members who meet NCQA/HEDIS criteria for diagnosis of polycystic ovaries any time during the Attributed Member s history through the end of the Measurement Period. AND exclude Attributed Members who meet NCQA/HEDIS criteria for diagnosis of gestational diabetes or steroid-induced diabetes in any setting, during the or the prior to the. National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 22 CB Version 070116 V1

Sub-composite: Annual Monitoring for Persistent Medications Measure Description / Technical Specifications Measure Citation Annual Monitoring for Patients on Persistent Medications: Digoxin Attributed Members age 18 or older who had at least a 50% medication possession ratio (MPR) for digoxin during the who had at least 1 serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) therapeutic monitoring test during the measurement. Attributed Members in the denominator who had at least one serum potassium and either a serum creatinine or a BUN test during the measurement Attributed Members who had at least a 50% MPR for digoxin during the 1 claims for a lab panel test AND 1 claims for a serum digoxin test during the OR 1 claims for a serum potassium test AND 1 claims for serum creatinine test AND 1 claims for a serum digoxin test during the Age 18 s as of the end of the measurement AND have service and Rx eligibility during the (HEDIS criteria) AND continuous Rx use of digoxin for at least 180 days during the AND no inpatient hospitalizations during the National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. Annual Monitoring for Patients on Persistent Medications: ACE/ARB Attributed Members age 18 or older who received at least a 50% medication possession ratio (MPR) for ACE inhibitors or ARBs during the measurement who had at least one serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) test during the. Attributed Members in the denominator who had at least one serum potassium and either a serum creatinine or a BUN test during the measurement Attributed Members who had at least a 50% MPR for ACE inhibitors or ARBs during the measurement 1 claims for a lab panel test during the OR BOTH 1 claims for a serum potassium test AND 1 claims for serum creatinine test during the Age 18 s as of the end of the measurement AND have service and Rx eligibility during the (HEDIS criteria) AND continuous Rx use of ACE/ARBs for at least 180 ambulatory treatment days during the last AND no inpatient hospitalizations during the National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 23 CB Version 070116 V1

Measure Description / Technical Specifications Measure Citation Annual Monitoring for Patients on Persistent Medications: Diuretics Attributed Members age 18 or older who had at least a 50% medication possession ratio (MPR) for diuretics during the who had at least 1 serum potassium and either a serum creatinine or a blood urea nitrogen (BUN) therapeutic monitoring test during the. Attributed Members in the denominator who had at least one serum potassium and either a serum creatinine or a BUN therapeutic monitoring test during the measurement Attributed Members who had at least a 50% MPR for diuretics during the 1 claims for a lab panel test during the OR BOTH 1 claims for a serum potassium test AND 1 claims for serum creatinine test during the Age 18 s as of the end of the measurement AND have service and Rx eligibility during the (HEDIS criteria) AND continuous Rx use of diuretics for at least 180 ambulatory treatment days during the last AND no inpatient hospitalizations during the National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 24 CB Version 070116 V1

Sub-composite: Other Acute and Chronic Care Measurement Measure Description / Technical Specifications Measure Citation Appropriate Testing for Children with Pharyngitis children 2 18 s of age who were diagnosed with pharyngitis prior to or during the measurement, dispensed an antibiotic, and had a test for group A streptococcus for the episode. Attributed Members in the denominator who had a test for group A streptococcus (strep) for the episode of pharyngitis Children age 2 to 18 who were diagnosed with pharyngitis and dispensed an antibiotic within six months prior to the or during the first 6 months of the 1 lab claim for a Group A strep test from 3 days before to 3 days after the date of onset of pharyngitis At least 2 s old 18 months prior to the end of the AND less than 18 s old 6 months prior to the end of the AND at least 1 medical claim for Pharyngitis as a solitary primary diagnosis between 30 and 365 days prior to the end of the, excluding claims from Acute Inpatient or an Outpatient facility that is followed by an ER visit within 2 days. Save earliest claim as Pharyngitis onset date AND have no Rx claims for an URI Antibiotic during the period of 30 days prior to Pharyngitis onset date but not including the onset date AND have service and Rx eligibility from 30 days before to 3 days after date of onset of pharyngitis AND have active Rx for an URI Antibiotic from 0 to 3 days after Pharyngitis onset date National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. Appropriate Treatment for Children with Upper Respiratory Infection children age 3 months to 18 s who were diagnosed with an upper respiratory infection (URI) who did not receive an antibiotic prescription within three days after diagnosis Attributed Members in the denominator who did not receive an antibiotic prescription within three days after the diagnosis Children age 3 months old as of 18 months prior to the end of the measurement to 18 s old 6 months prior to the end of the who were diagnosed with URI between 545 and 180 days prior to the end of the No claims for a URI Antibiotic between 0 and 3 days after the URI episode date At least 3 months old 18 months prior to the end of the AND less than 18 s old 6 months prior to the end of the AND meet criteria for URI according to HEDIS; must be a primary solitary diagnosis for URI, excluding claims from an Inpatient or an Outpatient facility that is followed by an ER visit within 2 days AND the URI episode date occurs between 545 and 184 days prior to the end of the measurement AND have member and Rx eligibility 30 days prior to 3 days after the URI episode date AND no Rx claims for an Antibiotic between 1 and 30 days prior to date of onset of URI AND no active days supply for an Antibiotic on the date of onset of URI AND no claims for a competing diagnosis based on HEDIS criteria on the URI episode date or 3 days following the URI episode date National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 25 CB Version 070116 V1

Measure Description / Technical Specifications Measure Citation Osteoporosis Management in Women Who Had a Fracture women age 67 or older who suffered a bone fracture and had either a bone mineral density (BMD) test or a prescription for a drug to treat or prevent osteoporosis during the six months after the date of fracture. Attributed Members in the denominator who had either a bone mineral density test or a prescription for a drug to treat or prevent osteoporosis in the 6 months after the date of fracture Women who are 67 s or older who suffered a bone fracture during the 6 months prior to the measurement or during the first 6 months of the measurement 1 claim for osteoporosis drugs from 0 to 180 days following the index episode of bone fracture OR at least 1 claim for a BMD test from 0 to 180 days following the index episode of bone fracture 67 to 85 s old as of the end of the AND Female AND had a claim for bone fracture during the 6 months prior to the through the first 6 months of the, with the earliest date of bone fracture diagnosis being the index episode AND no claims for bone fracture 60 days prior to the index episode AND had service and Rx eligibility between 12 months prior and 6 months after the index episode AND have no claims for a BMD test during the 730 days prior to the index episode or a prescription for a drug to treat or prevent osteoporosis during the 365 days prior to the index episode National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 26 CB Version 070116 V1

Measure Description / Technical Specifications Measure Citation Persistence of Beta-Blocker Treatment After a Heart Attack Attributed Members ages 18 or older who were hospitalized for AMI and discharged from the hospital between July 1 of the prior to the and June 30 of the who have been taking a beta blocker consistently for at least six months post discharge. Attributed Members in the denominator who have 135 days supply of a beta blocker medication in the six months post AMI discharge Attributed Members hospitalized and discharged with an AMI between July 1 of the prior to the and June 30 of the, who do not have a contraindication to beta blockers (contraindications include: history of asthma or use of asthma medications, hypotension, 2 nd - or 3 rd -degree heart block or sinus bradycardia with no history of pacemaker, or COPD) 135 days supply of a beta blocker medication during the 6 months following date of discharge of AMI Age 18 s as of the end of the measurement AND meet criteria for Acute MI AND date of discharge of AMI between 180 and 545 days prior to end of the AND have no absolute contraindications for beta blockers. These include diagnoses for asthma, COPD, heart block >1 degree, hypotension, and sinus bradycardia, and Rx codes for asthma medications AND have Rx eligibility during the 6 months following the AMI episode date National Committee for Quality Assurance. HEDIS 2015 Measures. Vol. 2. Washington, DC: National Committee for Quality Assurance; 2014. 27 CB Version 070116 V1

Measure Description / Technical Specifications Measure Citation Arthritis: Disease Modifying Antirheumatic Drug (DMARD) Therapy in RA Attributed Members with a diagnosis of RA and who were dispensed at least one ambulatory prescription for a diseasemodifying anti-rheumatic drug (DMARD) during the. Attributed Members in the denominator who were dispensed at least one ambulatory prescription for a disease-modifying antirheumatic drug (DMARD) during the Attributed Members 18 s old with two faceto-face physician encounters with different dates of service in an outpatient or non-acute inpatient setting during the first 11 months of the with any diagnosis of rheumatoid arthritis (RA). Excludes patients diagnosed with HIV or who were pregnant during the 1 Rx claim for DMARD during the Age 18 s old as of the end of the AND 2 medical claims for face-to-face physician encounters with different dates of service in an outpatient or non-acute inpatient setting, with a diagnosis of rheumatoid arthritis based on HEDIS criteria, during the first 11 months of the measurement AND no medical claims for HIV or pregnancy during the AND has continuous medical and Rx eligibility (as defined by NCQA/HEDIS) during the National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2014. 28 CB Version 070116 V1

Measure Description / Technical Specification Measure Citation Use of Appropriate Medications for People with Asthma Attributed Members age 5 to 56 during the who have persistent asthma and who were appropriately prescribed medication during the measurement. Attributed Members in the denominator who have at least one claim for an asthma controller medication. Attributed Members who meet HEDIS criteria for persistent asthma during or prior to the measurement with pharmacy benefits during the. Excludes Attributed Members with any history of emphysema, COPD, cystic fibrosis, and acute respiratory failure. Rx claim for HEDIS-defined asthma controller medication during the. Age 5 and 56 as of end of AND meet criteria for persistent asthma per HEDIS AND have service eligibility the prior to and during the measurement AND have Rx eligibility during the measurement AND no claims for asthma medication contraindications; these include emphysema, COPD, cystic fibrosis, and acute respiratory failure National Committee for Quality Assurance. HEDIS 2015. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol. 2, 2014. 29 CB Version 070116 V1